Researchers published in Nature Cancer report an Fc-optimized engineered GITR antibody that enhances antitumor immunity by strengthening communication between CD4 T cells and dendritic cells. The work focuses on glucocorticoid-induced tumor necrosis factor receptor–related protein (GITR) as an immunologic lever to amplify the collaboration needed for effective tumor responses. By improving the antibody’s Fc properties, the authors show strengthened cellular dialogue that translates into more robust immune activity in the reported study framework. For translational immuno-oncology, the approach continues a shift toward designing antibodies to improve not only target engagement, but also immune-cell orchestration. The results also provide a rationale for combination and sequencing strategies where checkpoint inhibitors and other modalities depend on competent antigen presentation and CD4-mediated help.